align semaglutide – Semaglutide dose may matter more

Increased fatigue

Moreover, it is now well established that the reversible formation of mixed disulfide GSSR through protein- S -glutathionylation is an important on/off mechanism for dynamic post-translational regulation of a variety of regulatory, structural and metabolic proteins involved in signaling and metabolic pathway in cell systems (Ghezzi, 2005, 2013)

Guidelines have evolved considerably from routine medication cessation in 2023 to GLP-1 RA continuation with individualised risk assessment in 20242025, illustrating increasing acknowledgment that certain theoretical risks may be underestimated

Inconsistent timing can cause those levels to fluctuate, which may chip away at how well the medication works over time

Non-pharmacological management is equally important and should include physiotherapy, occupational therapy, and patient education programmes

The most widely discussed newer agents are semaglutide (brand name Wegovy), a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the MHRA for chronic weight management in adults, and tirzepatide (brand name Mounjaro), a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist that has also received UK approval for weight management in adults